Roche, a Swiss multinational healthcare company, completed the acquisition of Carmot Therapeutics, a therapeutical company specialized in obesity and diabetes, for $3.1bn. “Obesity is a heterogeneous disease, which contributes to many other diseases that together comprise a significant health burden worldwide. By combining Carmot’s portfolio with programs in our Pharmaceuticals pipeline and our Diagnostics expertise and portfolio of products across cardiovascular and metabolic diseases, we are aiming to improve the standard of care and positively impact patients’ lives,” Thomas Schinecker, Roche Group CEO.